Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto are suing Monsanto in numerous state courts for failure to warn the public about the risk of cancer associated with the glyphosate-based weedkiller Roundup after the IARC report in 2015 linking glyphosate to cancer in humans. Monsanto denies that Roundup is carcinogenic. In March 2017, 40 plaintiffs filed a lawsuit at the Alameda County Superior Court, a branch of the California Superior Court, asking for damages caused by the company’s glyphosate-based weed-killers, including Roundup, and demanding a jury trial. On August 10, 2018, Monsanto lost the first decided case. Dewayne Johnson, who has non-Hodgkin's lymphoma, was initially awarded $289 million